Amgen's Q4 and full-year 2017 earnings call presented several key points that suggest a positive short-term outlook for the company's stock:

1. **Strong Financial Performance**: Despite some challenges, Amgen delivered strong financial results, including an 8% increase in non-GAAP EPS for the full year and a record non-GAAP operating margin of 53.5%[1][3][5].

2. **Tax Reform Benefits**: The company highlighted significant benefits from U.S. tax reform, including a more competitive tax rate, increased investments in innovation and advanced technologies, and enhanced capital deployment flexibility. This is expected to drive long-term growth and improve the company's financial performance[1][3].

3. **Product Performance and Pipeline**: Amgen's newer products, such as Repatha, Prolia, and KYPROLIS, showed strong growth. The inclusion of outcomes data in Repatha's label and the upcoming launches of Aimovig and AMGEVITA are expected to drive future growth. The pipeline is robust, with several promising products in various stages of development[1][3].

4. **Cash Flow and Share Repurchases**: The company generated $10.5 billion in free cash flow for the full year and announced an additional $10 billion share repurchase authorization, which indicates a commitment to returning capital to shareholders[1][3].

5. **Guidance and Outlook**: For 2018, Amgen provided guidance that includes revenue and non-GAAP EPS growth, albeit with some uncertainties related to biosimilar competition and litigation outcomes. However, the overall tone remains positive, with a focus on investing in growth and returning capital to shareholders[1][3].

Given these points, the short-term impact on Amgen's stock is likely to be positive, driven by strong financial performance, beneficial tax reform, a robust product pipeline, and significant share repurchase plans.

**Rating: 2**